Biomarker predicting the outcome of Androgen Deprivation Therapies and Chemotherapies in Prostate Cancer patients Cancer
Conditions
Interventions
All patients who underwent prostate biopsy were enrolled in this study.
The biopsied prostate cancer will be tested for several biomarkers. mRNA expression of targeted biomarkers are
Sponsors
Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan UGM
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Diagnosed with advanced prostate cancer 2. Aged 18 - 80 years
Exclusion criteria
Exclusion criteria: 1. Received systemic chemotherapy, targeted therapy, and immunomodulatory therapy prior study 2. Received local therapy including radical prostatectomy, radiotherapy, and other local therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Time to achieve Castration resistant therapy (CRPC). CRPC is defined as castrate level of serum testosterone 2 ng/mL, or (ii) radiological progression – the appearance of two or more bone lesions on bone scan or enlargement of a soft tissue lesion based on RECIST criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Progression-free survival (PFS) measured using the methods described in the primary outcome measure at the end of the study | — |
Countries
Indonesia
Contacts
Public ContactAndy;Indrawarman Zulfiqqar;Soehardjo
;
Outcome results
None listed